ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1725

The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL

Omer Nuri Pamuk1, Guray Can2, Suleyman Ayvaz3, Turan Karaca4, Gulsum Pamuk5, Selim Demirtas6 and George C. Tsokos7, 1Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 2Gastroenterology, Trakya University Medical Faculty, Edirne, Turkey, 3Pediatric Surgery, Trakya University Medical Faculty, Edirne, Turkey, 4Histology, Trakya University Medical Faculty, Edirne, Turkey, 5Hematology, Trakya University Medical Faculty, Edirne, Turkey, 6Trakya University Medical Faculty, Edirne, Turkey, 7Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, fibrosis and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose The possible antifibrotic effects of various kinase inhibitors has been studied before in SSc. Spleen tyrosine kinase (Syk) is a protein tyrosine kinase which activates intracellular signal transduction pathways and has been claimed to be involved in the pathogenesis of systemic autoimmune diseases. We investigated the ability of a small drug Syk inhibitor, fostamatinib, to protect mice from bleomycin-induced SSc.

Methods Four study groups of Balb/c mice were included in this study: control, bleomycin (administered subcutaneously to BALB/c mice for 21 days), bleomycin and fostamatinib (mice fed with chow containing a Syk inhibitor for 21 days) and fostamatinib alone groups. Skin and lung tissue specimens were obtained and evaluated histologically.

Results Mice treated with bleomycin alone had significantly more skin thickness (416.1±6.1) compared to control (260.1±10.1) and fostamatinib (254.3±7.9) treated mice (p<0.001). Mice subjected to bleomycin and fed with fostamatinib-containing chow generated more (312.3±4.4) dermal thickness than control and fostamatinib-treated mice (p values <0.001) but, significantly less when compared to mice treated with bleomycin alone (p<0.001).Alveolar hemorrhage, edema, damage and leukocyte scores in the lungs of mice treated with bleomycin were significantly higher v compared to control or fostamatinib alone-treated mice (p values <0.001). At the end of the 21-day bleomycin administration, there was apparent prominent fibrosis which was reduced significantly in the group of mice which received in parallel fostamatinib. Following fostamatinib treatment, Syk, phospho-Syk, and TGF-β expression decreased in both skin and lung tissues

Conclusion The Syk inhibitor fostamatinib prevented bleomycin-induced fibrosis and inflammation in the skin and the lung. The anti-fibrotic effect of fostamatinib is linked to reduced Syk phosphorylation and TGF-β expression. The Syk pathway appears as a potential molecular target for therapeutic intervention in SSc.


Disclosure:

O. N. Pamuk,
None;

G. Can,
None;

S. Ayvaz,
None;

T. Karaca,
None;

G. Pamuk,
None;

S. Demirtas,
None;

G. C. Tsokos,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-syk-inhibitor-fostamatinib-limits-tissue-damage-and-fibrosis-in-a-bleomycin-induced-scleroderma-mouse-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology